Literature DB >> 30883031

Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis.

Jon T Giles1, Mary Chester M Wasko2, Cecilia P Chung3, Moyses Szklo4, Roger S Blumenthal4, Amy Kao5, Sabahat Bokhari1, Afshin Zartoshti1, C Michael Stein3, Joan M Bathon1.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) patients with the lowest circulating low-density lipoprotein (LDL) concentrations are at heightened risk of cardiovascular events. However, the atherosclerosis burden within this subgroup is unknown.
METHODS: RA patients pooled from 4 cohort studies of cardiovascular disease (CVD; n = 546) were compared with non-RA controls from the Multi-Ethnic Study of Atherosclerosis (n = 5,279). Those taking lipid-lowering medications were excluded. Differences in cardiac computed tomography-derived Agatston coronary artery calcium (CAC) scores between the RA and control groups were compared across strata of LDL concentration.
RESULTS: Among those with low LDL concentrations (<70 mg/dl), mean adjusted CAC scores were >4-fold higher for RA patients than for controls (18.6 versus 4.6 Agatston units, respectively; P < 0.001), a difference significantly greater than that in any other LDL concentration stratum except LDL concentration ≥160 mg/dl. Similarly, 32% of the RA patients with low LDL concentration had a CAC score of ≥100 Agatston units compared with only 7% of controls in the same LDL concentration stratum (odds ratio 5.97; P < 0.001), a difference significantly greater than that in all of the other LDL concentration strata. Low LDL concentration was most strongly associated with higher CAC score among RA patients who were white, had ever smoked, or were not obese. Other than a higher frequency of current smokers, RA patients with low LDL concentrations did not have more CVD risk factors or higher measures of RA disease activity or severity than RA patients with higher LDL concentrations.
CONCLUSION: RA patients with low LDL concentration may represent a group for whom heightened screening and prevention of atherosclerotic CVD is appropriate.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30883031      PMCID: PMC6716986          DOI: 10.1002/art.40889

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  33 in total

1.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors.

Authors:  Misato Hashizume; Masahiko Mihara
Journal:  Cytokine       Date:  2012-03-19       Impact factor: 3.861

3.  Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Eric L Matteson; Veronique L Roger; Terry M Therneau; Sherine E Gabriel
Journal:  Am J Cardiol       Date:  2012-04-20       Impact factor: 2.778

4.  Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Maureen McMahon; Jennifer Grossman; John FitzGerald; Erika Dahlin-Lee; Daniel J Wallace; Bernard Y Thong; Humeira Badsha; Kenneth Kalunian; Christina Charles; Mohamad Navab; Alan M Fogelman; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2006-08

5.  Low levels of low-density lipoprotein cholesterol: a negative predictor of survival in elderly patients with advanced heart failure.

Authors:  Gideon Charach; Alexander Rabinovich; Argov Ori; Dov Weksler; David Sheps; Lior Charach; Moshe Weintraub; Jacob George
Journal:  Cardiology       Date:  2013-11-05       Impact factor: 1.869

6.  Comparison of coronary artery calcium scores between electron beam computed tomography and 64-multidetector computed tomographic scanner.

Authors:  Song S Mao; Raveen S Pal; Charles R McKay; Yan G Gao; Ambarish Gopal; Naser Ahmadi; Janis Child; Sivi Carson; Junichiro Takasu; Behnaz Sarlak; Daniel Bechmann; Matthew Jay Budoff
Journal:  J Comput Assist Tomogr       Date:  2009 Mar-Apr       Impact factor: 1.826

7.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  J Antonio Aviña-Zubieta; Hyon K Choi; Mohsen Sadatsafavi; Mahyar Etminan; John M Esdaile; Diane Lacaille
Journal:  Arthritis Rheum       Date:  2008-12-15

8.  Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis.

Authors:  Amy H Kao; Shanthi Krishnaswami; Amylynn Cunningham; Daniel Edmundowicz; Penelope A Morel; Lewis H Kuller; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2008-01       Impact factor: 4.666

9.  Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids).

Authors:  Mohamed B Elshazly; Seth S Martin; Michael J Blaha; Parag H Joshi; Peter P Toth; John W McEvoy; Mohammed A Al-Hijji; Krishnaji R Kulkarni; Peter O Kwiterovich; Roger S Blumenthal; Steven R Jones
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

10.  Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.

Authors:  Iris Navarro-Millán; Shuo Yang; Scott L DuVall; Lang Chen; John Baddley; Grant W Cannon; Elizabeth S Delzell; Jie Zhang; Monika M Safford; Nivedita M Patkar; Ted R Mikuls; Jasvinder A Singh; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2015-01-21       Impact factor: 19.103

View more
  7 in total

1.  Positive effect of hydroxychloroquine on lipid profiles of patients with rheumatoid arthritis: A Veterans Affair cohort.

Authors:  Myriam Guevara; Bernard Ng
Journal:  Eur J Rheumatol       Date:  2020-11-05

2.  Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study ‒ ELSA-Brasil.

Authors:  Isabela M Bensenor; Alessandra C Goulart; Alexandre C Pereira; André R Brunoni; Airlane Alencar; Raul D Santos; Márcio S Bittencourt; Rosa W Telles; Luciana Andrade Carneiro Machado; Sandhi Maria Barreto; Bianca de Almeida-Pititto; Carolina Porto Silva Janovsky; José Augusto Sgarbi; William R Tebar; Vandrize Meneghini; Fernando Barbosa Junior; Ana Cristina de Medeiros Ribeiro; Sandra Gofinet Pasoto; Rosa Maria R Pereira; Eloísa Bonfá; Aytan M Sipahi; Itamar de S Santos; Paulo A Lotufo
Journal:  Clinics (Sao Paulo)       Date:  2022-04-06       Impact factor: 2.365

Review 3.  Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.

Authors:  Jianmin Chen; Lucy V Norling; Dianne Cooper
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600

4.  Lipid profiles and outcomes of patients with prior cancer and subsequent myocardial infarction or stroke.

Authors:  Chieh Yang Koo; Huili Zheng; Li Ling Tan; Ling-Li Foo; Raymond Seet; Jun-Hua Chong; Derek J Hausenloy; Wee-Joo Chng; A Mark Richards; Chi-Hang Lee; Mark Y Chan
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

Review 5.  Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial.

Authors:  Jon T Giles; Pamela M Rist; Katherine P Liao; Ahmed Tawakol; Zahi A Fayad; Venkatesh Mani; Nina P Paynter; Paul M Ridker; Robert J Glynn; Fengxin Lu; Rachel Broderick; Meredith Murray; Kathleen M M Vanni; Daniel H Solomon; Joan M Bathon
Journal:  ACR Open Rheumatol       Date:  2021-05-01

6.  Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?

Authors:  Ana M Fernández-Ortiz; Ana M Ortiz; Silvia Pérez; Esther Toledano; Lydia Abásolo; Miguel A González-Gay; Santos Castañeda; Isidoro González-Álvaro
Journal:  Arthritis Res Ther       Date:  2020-09-11       Impact factor: 5.156

Review 7.  Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment.

Authors:  Anne Mirjam Kerola; Silvia Rollefstad; Anne Grete Semb
Journal:  Eur Cardiol       Date:  2021-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.